$2.9 Bn Clinical Trial Supplies Markets by Services (Manufacturing, Packaging, Logistics, Distribution), Phases (I to IV), Type (Small molecule, Biologics, Medical Devices) – Global Forecast 2026 – ResearchAndMarkets.com

$2.9 Bn Clinical Trial Supplies Markets by Services (Manufacturing, Packaging, Logistics, Distribution), Phases (I to IV), Type (Small molecule, Biologics, Medical Devices) – Global Forecast 2026 – ResearchAndMarkets.com




$2.9 Bn Clinical Trial Supplies Markets by Services (Manufacturing, Packaging, Logistics, Distribution), Phases (I to IV), Type (Small molecule, Biologics, Medical Devices) – Global Forecast 2026 – ResearchAndMarkets.com

DUBLIN–(BUSINESS WIRE)–The “Clinical Trial Supplies Market by Services (Manufacturing, Packaging, Logistics, Distribution), Phases (I to IV), Type (Small molecule, Biologics, Medical Devices) Therapeutic Areas (Oncology, CNS, CVD, Infectious, Immunology) – Global Forecast 2026” report has been added to ResearchAndMarkets.com’s offering.

The global clinical trial supplies market is projected to reach USD 2.9 billion by 2026 from USD 1.9 billion in 2021, at a CAGR of 8.5% during the forecast period of 2021 to 2026.

Market growth is largely driven by the increasing R&D expenditure in pharmaceutical and biopharmaceutical companies and the growing number of clinical trials conducted globally. However, the increasing cost of drug development and clinical trials is expected to restrain the growth of this market during the forecast period.

The logistics and distribution segment accounted for the highest growth rate in the clinical trial supplies market, by service, during the forecast period

In 2020, the logistics & distribution services segment accounted for the largest share (26.3%) of the clinical trial supplies market, mainly due to the globalization of clinical trials, the increasing number of trials involving temperature-sensitive products, the highly regulated nature of the market, and expertise of supply companies in terms of therapeutic areas and geographical reach. The growth of the fastest-growing segment was attributed to the increasing number of clinical trials conducted and the decentralization of the trials across the globe.

Oncology segment accounted for the largest share of the therapeutic area segment

Based on the therapeutic area, the clinical trial supplies market is segmented into oncology, CNS & mental disorders, cardiovascular diseases, digestive disorders, infectious diseases, metabolic disorders, immunology, blood disorders, and other therapeutic areas (respiratory disorders, dermatological disorders, rare diseases, ENT diseases, Nephrology).

Oncology is the largest segment in this market owing to the high and growing number of research studies on cancer therapeutics and the increasing number of companies focusing on bringing innovative cancer drugs into the market. Also, the high incidence and prevalence of cancer, healthcare systems across the globe are focusing on reducing the burden of cancer by adopting innovative diagnostic and therapeutic approaches is a driver.

In this scenario, effective drugs might witness widespread adoption in major markets such as the US, Europe, and the Asia Pacific. Considering these factors, many pharmaceutical companies are making significant investments in the development of innovative cancer drugs.

Asia Pacific: The fastest-growing region in the clinical trial supplies market

The clinical trial supplies market is segmented into North America, Europe, Asia Pacific, RoW. The APAC market, on the other hand, is expected to be the fastest-growing regional segment during the forecast period owing to increasing investments and expansions by big pharma companies in countries such as China, India, and South Korea.

Prominent players operating in the global clinical trial supplies market include Catalent, Inc. (US), Thermo Fisher Scientific (US), Piramal Pharma Solutions (India), Parexel International Corporation (US), and UDG Healthcare (Ireland), Almac Group (UK), Biocair (UK), Eurofins (France).

Market Dynamics

Drivers

  • Increasing R&D Expenditure of Pharmaceutical and Biopharmaceutical Companies
  • Increasing Number of Registered Clinical Trials
  • Increasing Decentralization of Clinical Trials

Restraints

High Cost of Drug Development

Opportunities

  • Emerging Markets

Lists of Companies Profiled in the Report:

  • Thermo Fisher (US)
  • Catalent, Inc. (US)
  • Parexel (US)
  • Eurofins (France)
  • UDG Healthcare (Ireland)
  • Piramal Pharma Solutions (India)
  • Almac Group (UK)
  • PCI Pharma Services (US)
  • PRA Health Sciences (US)
  • Biocair (UK), Eurofins (France)
  • Marken (US)
  • Infosys (India)
  • Liveo Research (India)
  • Capsugel (a Lonza Group company) (Switzerland)
  • SIRO Clinpharm (India)
  • KLIFO A/S (Denmark)
  • Clinigen (UK)
  • Ancillare (US)
  • N-SIDE (Belgium)
  • ADAllen (UK)
  • Rubicon (India)
  • Durbin (UK)
  • Recipharm (Sweden)
  • Seveillar (India)
  • Myonex (India)

For more information about this report visit https://www.researchandmarkets.com/r/ajnrvz

 

Contacts

ResearchAndMarkets.com

Laura Wood, Senior Press Manager

press@researchandmarkets.com

For E.S.T Office Hours Call 1-917-300-0470

For U.S./CAN Toll Free Call 1-800-526-8630

For GMT Office Hours Call +353-1-416-8900